Failure to Rotate Insulin Injection Sites
Summary
The facility failed to ensure two sampled residents were free from significant medication errors related to insulin administration. For Resident 8, who had type 2 diabetes mellitus, intact cognition, and the capacity to understand and make decisions, the record showed an order for insulin glargine 19 units subcutaneously at bedtime with instructions to hold if blood glucose was less than 100 mg/dl. The Location of Administration Report showed repeated insulin injections in the same abdominal quadrants during January 2026, including multiple administrations in the left upper quadrant, right lower quadrant, right upper quadrant, and left lower quadrant without rotation between sites as documented. During a concurrent interview and record review, RN 1 stated there were multiple instances in January 2026 when Resident 8's insulin administration sites were not rotated. RN 1 stated insulin is a significant medication and that sites should be rotated to prevent skin lumps that can affect absorption, and stated that not rotating insulin sites is a medication error. The DON also stated that Resident 8's insulin sites should have been rotated to prevent lipodystrophy and that administering insulin on sites with lipodystrophy can cause malabsorption and hypo/hyperglycemia. The DON stated the licensed staff did not follow the facility's policy and procedure titled Timely Administration of Insulin or the facility-provided highlights of prescribing information for Lantus. For Resident 2, who had diagnoses including DM 2, difficulty walking, and generalized muscle weakness, the record indicated intact cognition and the ability to understand and make needs known, and that the resident received insulin. The DON stated that Resident 2's insulin lispro and Lantus administration sites were not rotated for March 2026. The DON stated insulin should be administered on clean sites and rotated to prevent lipodystrophy, and that failure to rotate sites can result in improper absorption and ineffective insulin action, which could lead to hypo or hyperglycemia. The facility's policies on Timely Administration of Insulin and Medication Errors, along with the manufacturer information for Lantus and insulin lispro, stated that injection sites should be rotated to reduce the risk of lipodystrophy.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.